-PTI The condition of government hospitals in Delhi drew a sharp criticism from Comptroller and Auditor General (CAG), which, in its report found several glaring shortcomings like unavailability of blood banks in five hospitals. The CAG today painted a sorry state of affairs at government hospitals in the national capital in its report for the fiscal year ending March 2012, which was tabled in Delhi Assembly. The government auditor said that scrutiny of...

-The Times of India The Supreme Court on Monday rejected pharma giant Novartis AG's plea to preserve its patent over a life-saving cancer drug, Glivec, drawing a huge sigh of relief from thousands of patients in India and in dozens of developing countries as the fear of an almost 15-fold escalation of drug costs receded. It is the biggest setback for multinational pharma companies, which have been denied patent protection...

-The Hindu   The government does it purely on the strength of a CERTificate issued by the district administration Even as the recent affidavit submitted by the Union Ministry of Environment and Forests (MoEF) before the Supreme Court in the Vedanta case has caused dismay among tribal communities and activists for the dilution of its stand on diverting forest lands of tribal communities, the Ministry has gone a step further and allowed diversion...

-The Hindu   Supreme Court rejects Novartis' plea for patent; green signal for cheaper generic drugs In a ruling that will help patients continue to buy several life-saving medicines as generic drugs, the Supreme Court on Monday held that the modification of a well known cancer-fighting drug is not a patentable new invention. The judgment allows suppliers to continue making generic copies of Swiss firm Novartis' Glivec or Gleevec, which has been shown to...

-Live Mint SC rejects Novartis's patent plea for Glivec, says it does not meet any standard of novelty or inventiveness In a landmark judgement, India's apex court rejected Swiss drug maker Novartis AG's legal challenge aimed at securing a patent for blockbuster anti-cancer drug imatinib mesylate, branded Glivec in the country. The verdict, which is seen as a setback to multinational pharmaceutical companies operating in India, may influence a rash of pending disputes...